Factors associated with willingness to take extended release naltrexone among injection drug users

被引：26

作者：

Ahamad K. ^{[1
,2
]}

Milloy M.J. ^{[1
]}

Nguyen P. ^{[1
]}

Uhlmann S. ^{[1
]}

Johnson C. ^{[1
]}

Korthuis T.P. ^{[4
,5
]}

Kerr T. ^{[1
]}

Wood E. ^{[1
,3
,6
]}

机构：

[1] British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 1081 Burrard Street, Vancouver, V6Z 1Y6, BC

[2] Department of Family Practice, University of British Columbia, 5950 University Boulevard Street, Vancouver, V6T 1Z3, BC

[3] Department of Medicine, University of British Columbia, 2775 Laurel Street, Vancouver, V5Z 1M9, BC

[4] Department of Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, 97239, OR

[5] Department of Public Health-Preventive Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, 97239, OR

[6] Division of Epidemiology and Population Health, BC Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, V6Z 1Y6, BC

来源：

Addiction Science & Clinical Practice | / 10卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Addiction; Opioid antagonist; Willingness to take;

D O I：

10.1186/s13722-015-0034-5

中图分类号：

学科分类号：

摘要：

Background: Although opioid-agonist therapy with methadone or buprenorphine/naloxone is currently the mainstay of medical treatment for opioid use disorder, these medications often are not well accepted or tolerated by patients. Recently, extended release naltrexone (XR-NTX), an opioid antagonist, has been advanced as an alternative treatment. The willingness of opioid-addicted patients to take XR-NTX has not been well described. Methods: Opioid-using persons enrolled in a community-recruited cohort in Vancouver, Canada, were asked whether or not they would be willing to take XR-NTX. Logistic regression was used to independently identify factors associated with willingness to take the medication. Results: Among the 657 participants surveyed between June 1, 2013, and November 30, 2013, 342 (52.1%) were willing to take XR-NTX. One factor positively associated with willingness was daily heroin injection (adjusted odds ratio [AOR] = 1.53; 95% confidence interval [CI] = 1.02-2.31), whereas Caucasian ethnicity was negatively associated (AOR = 0.59; 95% CI = 0.43-0.82). Satisfaction with agonist therapy (13.4%) and unwillingness to stop opioids being used for pain (26.9%) were the most common reasons for being unwilling to take XR-NTX. Conclusions: A high level of willingness to take XR-NTX was observed in this setting. Interestingly, daily injection heroin use was positively associated with willingness, whereas Caucasian participants were less willing to take XR-NTX. Although explanations for unwillingness were described in this study, further research is needed to investigate real-world acceptability of XR-NTX as an additional option for the treatment of opioid use disorder. © 2015 Ahamad et al.; licensee BioMed Central.

引用

共 30 条

[1]

World Drug Report 2014, (2014)

[2]

Jones C.M., Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers-United States, 2002-2004 and 2008-2010, Drug Alcohol Depend, 132, 1, pp. 95-100, (2013)

[3]

Ling W., Hillhouse M., Ang A., Jenkins J., Fahey J., Comparison of behavioral treatment conditions in buprenorphine maintenance, Addiction, 108, 10, pp. 1788-1798, (2013)

[4]

Mattick R.P., Breen C., Kimber J., Davoli M., Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence, Cochrane Library, (2014)

[5]

Marsch L.A., The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis, Addiction, 93, 4, pp. 515-532, (1998)

[6]

Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R., Et al., Methadone and Buprenorphine for the Management of Opioid Dependence: A Systematic Review and Economic Evaluation, (2007)

[7]

Weiss R.D., Potter J.S., Fiellin D.A., Byrne M., Connery H.S., Dickinson W., Et al., Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial, Arch Gen Psychiatry, 68, 12, pp. 1238-1246, (2011)

[8]

Peterson J.A., Schwartz R.P., Mitchell S.G., Reisinger H.S., Kelly S.M., O'Grady K.E., Et al., Why don't out-of-treatment individuals enter methadone treatment programmes?, Int J Drug Policy, 21, 1, pp. 36-42, (2010)

[9]

Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., Bigelow G.E., A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence, N Engl J Med, 343, 18, pp. 1290-1297, (2000)

[10]

Strain E.C., Bigelow G.E., Liebson I.A., Stitzer M.L., Moderate-vs high-dose methadone in the treatment of opioid dependence: A randomized trial, JAMA, 281, 11, pp. 1000-1005, (1999)

← 1 2 3 →